Sutro Biopharma, Inc.
https://www.sutrobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sutro Biopharma, Inc.
ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer
The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.
Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher that speeds up a regulatory review in the US is about $100m but the France-headquartered firm has managed to get considerably more from an unnamed big pharma.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice